RosenH. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429-2438. doi:10.1056/NEJMcp1006613.
2.
ButiMRiveiro-BarcielaMEstebanR. Management of direct antiviral agents failures. J Hepatol. 2015;63:1511-1522. doi:10.1016/j.jhep.2015.08.010.
3.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-954. doi:10.1002/hep.27950.
4.
AbergelAAsselahTMetivierS. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16:459-464. doi:10.1016/S1473-3099(15)00529-0.
5.
LawitzEMangiaAWylesD. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887. doi:10.1056/NEJMoa1214853.
6.
LawitzESulkowskiMSGhalibR. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-1765. doi:10.1016/S0140-6736(14)61036-9.
7.
PapastergiousVKaratapanisS. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases. 2015;3:2010-2020. doi:10.12998/wjcc.v3.i3.210.
8.
HezodeCBronowickyJ-P. Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol. 2016;64:212-225. doi:10.1016/j.jhep.2015.09.009.
9.
SlimJAfridiMS. Managing adverse effects of interferon alfa and ribavirin in combination therapy for HCV. Infect Dis Clin N Am. 2012;26:917-929. doi:10.1016/j.idc.2012.08.006.
10.
PapadopoulosNDeutschMGeorgalasAPoulakidasHKarnesisL. Simeprevir and sofosbuvir combination treatment in a patient with HCV cirrhosis and HbS Beta 0 thalassemia: efficacy and safety despite baseline hyperbilirubinemia. Case Rep Hematol. 2016;2016:7635128. doi:10.1155/2016/7635128.
